Researchers say study results provide a clear rationale for developing therapies that target LCN2 in lung cancer patients.
The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...
Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures. Immunotherapy is changing treatment ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.
Neoadjuvant pembrolizumab (3 doses) in stage I–III disease yielded a 71% pCR rate and only one melanoma-specific survival event at 3 years post-resection. Experts discuss the SWOG S1512 trial of ...
Hosted on MSN
Modern cancer care explained: How robotic surgery and new therapies preserve quality of life
Cancer treatment has changed dramatically over the past decade. What was once dominated by extensive surgeries followed by aggressive chemotherapy and radiation has now evolved into a more balanced, ...
Aug. 4 (UPI) --Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks reluctant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results